![UMN logo](/assets/logo-14ca9c5bc764343ea0b1ec3edef3d39b15c438f8eb603b1a5fbf826128a74246.png)
Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)
![](/assets/flag-998f631fa7bef54098575ae881e66e71315bfae4a5d1ffb34ab8f527fcff0600.jpg)
The specific aims of the trial are to prospectively study nonischemic cardiomyopathy patients qualified for CRT-D following currently approved standard indications in order to: 1) Validate the MADIT-CRT-derived model predicting fast VT/VF in nonischemic cardiomyopathy patients with QRS≥120 ms. 2) Determine whether CMR added to the risk model validated in specific aim 1 will further improve risk stratification for predicting fast VT/VF in nonischemic cardiomyopathy patients with QRS≥120ms. 3) Evaluate costs of risk stratification using Holter and CMR in relationship to costs of implanted devices without risk stratification.
• At least 21 years of age
• Diagnosed with nonischemic dilated cardiomyopathy (NICM)
• On optimal medications for management
• If a cardiac defibrillator hasn't been implanted, must be willing to have a cardiac defibrillator implanted within 3 months of study enrollment
• If a cardiac defibrillator has been implanted, it must be more recent than July 1, 2018
• Nonischemic cardiomyopathy due to other known causes such as amyloidosis, sarcoidosis, cardiotoxicity due to chemotherapy, hypertrophic cardiomyopathy,
• History of prior myocardial infarction, percutaneous coronary intervention, or coronary bypass grafting
• History of ablation to treat ventricular fibrillation
Heart & Vascular
Clinics and Surgery Center (CSC), Implantable cardioverter defibrillator (ICD), Nonischemic dilated cardiomyopathy (NICM)